We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?
Read MoreHide Full Article
Esperion Therapeutics shares soared 5.7% in the last trading session to close at $7.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.9% gain over the past four weeks.
The surge in stock price is attributable to investor’s positive outlook for Esperion’s performance in the second half of 2022. The company which currently has two FDA-approved drugs — Nexletol and Nexlizet — in its portfolio is also attracting investors due to its pipeline progress.
This biopharmaceutical company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +64.9%. Revenues are expected to be $20.07 million, up 39.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Esperion Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ESPR going forward to see if this recent jump can turn into more strength down the road.
Esperion Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Ionis Pharmaceuticals (IONS - Free Report) , closed the last trading session 2.5% higher at $47.41. Over the past month, IONS has returned 4.4%.
For Ionis Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +0.6% over the past month to -$0.71. This represents a change of -22.4% from what the company reported a year ago. Ionis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?
Esperion Therapeutics shares soared 5.7% in the last trading session to close at $7.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.9% gain over the past four weeks.
The surge in stock price is attributable to investor’s positive outlook for Esperion’s performance in the second half of 2022. The company which currently has two FDA-approved drugs — Nexletol and Nexlizet — in its portfolio is also attracting investors due to its pipeline progress.
This biopharmaceutical company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +64.9%. Revenues are expected to be $20.07 million, up 39.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Esperion Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ESPR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Esperion Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Ionis Pharmaceuticals (IONS - Free Report) , closed the last trading session 2.5% higher at $47.41. Over the past month, IONS has returned 4.4%.
For Ionis Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +0.6% over the past month to -$0.71. This represents a change of -22.4% from what the company reported a year ago. Ionis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).